NP 500
Alternative Names: NP-500Latest Information Update: 28 Apr 2022
At a glance
- Originator Unknown
- Developer Napo Pharmaceuticals
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)
- 01 Jun 2021 Napo Pharmaceuticals has patent protection for NP 500 covering its formulation and use in USA
- 22 Apr 2020 Jaguar Health announces intention to submit IND to the US FDA for Type-2 diabetes mellitus